D

DeepCure

Biotech & Life Sciences · Boston, United States · Founded 2018

DeepCure, a biotechnology firm established in 2018, is strategically positioned at the intersection of artificial intelligence and drug discovery. The company was founded by a team with deep expertise in computational and medicinal chemistry, including CEO Kfir Schreiber, CSO Thrasyvoulos Karydis, and CIO Joseph Jacobson. Schreiber's background includes work at the MIT Media Lab and founding multiple companies, while Karydis brings experience from MIT and CERN, and Jacobson is a renowned inventor from the MIT Media Lab. This collective expertise underpins the company's foundational mission to revolutionize the creation of small molecule therapeutics. The core of DeepCure's operation is its proprietary AI-driven drug discovery platform. This platform integrates physics-based molecular modeling with advanced AI algorithms and a fully automated robotic wet lab for chemical synthesis. This combination aims to significantly accelerate the process of identifying and developing novel drug candidates by rapidly iterating through design-make-test cycles. The platform's capabilities allow for the exploration of a vast chemical space to design molecules with specific properties, overcoming traditional limitations in drug discovery. The company's business model is centered on developing a pipeline of proprietary drug candidates and potentially partnering with larger pharmaceutical companies for later-stage development and commercialization. DeepCure's therapeutic focus is on developing treatments for immune and inflammatory diseases. Its pipeline includes an oral STAT6 inhibitor program, which has generated multiple novel chemical scaffolds targeting a key pathway in allergic and inflammatory responses. Another key asset is its oral BRD4(BD2) program, which has produced what is described as the first truly selective inhibitor for this target, potentially offering a new approach for treating inflammatory conditions with a better safety profile. The company has announced its intention to advance its first drug candidates into clinical trials starting in 2025. This milestone is supported by significant financial backing, including a $40 million Series A funding round co-led by Morningside Ventures and TLV Partners, bringing its total funding to $47 million. Keywords: drug discovery, AI therapeutics, small molecules, automated synthesis, computational chemistry, STAT6 inhibitors, BRD4 inhibitors, immunology, inflammatory diseases, biotechnology